The role of glitazones in management of type 2 diabetes. A DREAM or a nightmare?

Obesity Reviews

Volumn 8, Issue 5, 2007, Pages 381-384

  Lindberg, M ^a   Astrup, A ^b  

^a DANISH MEDICINES AGENCY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glitazones; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ADVERSE OUTCOME; BLOOD PRESSURE; BODY WEIGHT; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FLUID RETENTION; FRACTURE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; LIVER FAILURE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; OBESITY; SAFETY; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 34548011678     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2007.00399.x     Document Type: Review

References (15)

1. The UKPDS Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 : 854 865.
2. Macfarlane DP, Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure: implications of emerging data. Am J Cardiovasc Drugs 2006 6 : 297 304.
3. Gale EAM. Lessons from the glitazones: a story of drug development. Lancet 2001 357 : 1870 1875.
4. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive investigators. Secondary prevention Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events). Lancet 2005 366 : 1279 1289.
5. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006 355 : 2427 2443.
6. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 368 : 1096 1105.
7. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene APR, Oactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive). Diabetes Care 2004 27 : 1647 1653.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from Cardiovaskular causes. N Engl J Med 2007 356 : 2457 2471.
9. Krall RL. Cardiovascular safety of rosiglitazone. Lancet 2007 Published online 30 May 2007 DOI: 10.1016/S0140-6736(07)60824-1.
10. Takeda Pharmaceuticals North America Inc. Re: Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with ACTOS (Pioglitazone HOI) Tablets for Type 2 Diabetes Mellitus. [Letter]. 2007. [WWW document]. URL http://www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf (accessed March 2007).
11. Federal Drug Administration, FDA. Safety Alert 2007-02-20. 2007. [WWW document]. URL http://www.fda.gov/medwatch/safety/2007/safety07. htm#rosiglitazone (accessed 20 February 2007).
12. Federal Drug Administration, FDA. Safety Alert 2007-03-09. 2007. [WWW document]. URL http://www.fda.gov/medwatch/safety/2007/safety07.htm#Actos (accessed 9 March 2007).
13. El-Hage J. Preclinical and Clinical Safety Assessments for PPAR Agonists. Center for Drug Evaluation and Research, FDA. 2004. [WWW document]. URL http://www.fda.gov/cder/present/DIA2004/Elhage.ppt (accessed 14 June 2007).
14. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2006 16 : 485 492.
15. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007 25 : 1476 1481.